Ссылки

1.Smith R. A ripping yarn of editorial misconduct. BMJ. Group blogs. 2008 Oct 21.

2.Smith R. The Trouble with Medical Journals. London: Royal Society of Medicine; 2006.

3.Schafer A. Biomedical conflicts of interest: a defence of the sequestration thesis – learning from the cases of Nancy Olivieri and David Healy. J Med Ethics. 2004; 30: 8–24.

4.Uniform Requirements for Manuscripts Submitted to Biomedical Journals: writing and editing for biomedical publication. February 2006. International Committee of Medical Journal Editors website. Available online at: www.icmje.org (accessed 23 January 2006).

5.Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med. 2005; 2: e138.

6.Smith R., Roberts I. Patient safety requires a new way to publish clinical trials. PLoS Clin Trials. 2006; 1(1): e6.

7.Wilkes M. S., Doblin B. H., Shapiro M. F. Pharmaceutical advertisements in leading medical journals: experts’ assessments. Ann Intern Med. 1992; 116: 912–19.

8.Lexchin J., Light D. W. Commercial infl uence and the content of medical journals. BMJ. 2006; 332: 1444–7.

9.Lundh A., Barbateskovic M., Hrybjartsson A., et al. Conflicts of interest at medical journals: the infl uence of industry-supported randomised trials on journal impact factors and revenue – cohort study. PLoS Med. 2010;

7:e1000354.

10.Drazen J. M., Curfman G. D. Financial associations of authors. N Engl J Med. 2002; 346: 1901–2.

11.Kassirer J. What the New England Journal of Medicine did. BMJ. 2011; 343: d5665.

12.Horton R. The dawn of McScience. New York Rev Books. 2004;

51:7–9.

13.Eaton L. Editor claims drug companies have a ‘parasitic’ relationship with journals. BMJ. 2005; 330: 9.

14.Handel A. E., Patel S. V., Pakpoor J., et al. High reprint orders in medical journals and pharmaceutical industry funding: case-control study.

BMJ. 2012; 344: e4212.

15.Hrybjartsson A., Gøtzsche P. C. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001; 344: 1594–602.

16.Jørgensen K. J., Johansen H. K., Gøtzsche P. C. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev. 2006; 1: CD004707.

17.Walsh T. J., Pappas P., Winston D. J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002; 346: 225–34.

18.Herbrecht R., Denning D. W., Patterson T. F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347: 408–15.

19.Jørgensen K. J., Johansen H. K., Gøtzsche P. C. Flaws in design, analysis and interpretation of Pfizer’s antifungal trials of voriconazole and uncritical subsequent quotations. Trials. 2006, 7: 3.

20.Johansen H. K., Gotzsche P. C. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999; 282: 1752–9.

21.Calverley P. M., Anderson J. A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356: 775–89.

22.Suissa S., Ernst P., Vandemheen K. L., et al. Methodological issues in therapeutic trials of COPD. Eur Respir J. 2008; 31: 927–33.

23.Bero L. A., Galbraith A., Rennie D. The publication of sponsored symposiums in medical journals. N Engl J Med. 1992; 327: 1135–40.

24.Cho M. K., Bero L. A. The quality of drug studies published in symposium proceedings. Ann Intern Med. 1996; 124: 485–9.

25.Lenzer J. Editor earned over $20m in royalties and $2m in fees from device manufacturer. BMJ. 2010; 340: c495.

26.Carragee E. J., Hurwitz E. L., Weiner B. K. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011; 11: 471–91.

27.Abbasi K. Editor’s choice: a tough nut to crack. BMJ. 2005; 330:

Jan 29.

28.Abramson J. Overdo$ed America: the broken promise of American medicine. New York: HarperCollins; 2004.